Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

chronic spontaneous urticaria (CSU), and chronic obstructive pulmonary disease (COPD) in different age populations. More than 1,000,000 patients are being treated with Dupixent globally.

DUPIXENT is used to reduce the number of flare-ups (the worsening of your COPD symptoms for several days) and can improve your breathing. It is not known if DUPIXENT is safe and effective in ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Several of the value domains address how much more productive COPD patients can expect to become over their lifetimes by adding Dupixent. The estimates include 400 more hours of occupational labor ...

Dupixent was previously granted Orphan Drug ... spontaneous urticaria (CSU), and chronic obstructive pulmonary disease (COPD) in different age populations. More than 1,000,000 patients are being ...